Renaissance Technologies LLC Lowers Stake in Ikena Oncology, Inc. (NASDAQ:IKNA)

Renaissance Technologies LLC lessened its stake in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 38.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 476,400 shares of the company's stock after selling 300,200 shares during the period. Renaissance Technologies LLC owned 0.99% of Ikena Oncology worth $786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. BBR Partners LLC bought a new position in shares of Ikena Oncology during the 2nd quarter worth approximately $33,000. JBF Capital Inc. purchased a new stake in shares of Ikena Oncology during the 2nd quarter valued at $120,000. Marquette Asset Management LLC acquired a new stake in shares of Ikena Oncology in the 1st quarter worth $104,000. Deuterium Capital Management LLC acquired a new stake in shares of Ikena Oncology in the 2nd quarter worth $133,000. Finally, Acadian Asset Management LLC grew its stake in Ikena Oncology by 1,201.8% during the 1st quarter. Acadian Asset Management LLC now owns 282,782 shares of the company's stock worth $400,000 after buying an additional 261,060 shares during the last quarter. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Stock Performance

NASDAQ IKNA traded up $0.01 during trading hours on Tuesday, reaching $1.70. The stock had a trading volume of 39,120 shares, compared to its average volume of 270,637. Ikena Oncology, Inc. has a 52-week low of $1.02 and a 52-week high of $4.63. The stock has a fifty day moving average of $1.69 and a 200 day moving average of $1.58. The stock has a market cap of $82.04 million, a P/E ratio of -1.06 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.04. On average, equities research analysts forecast that Ikena Oncology, Inc. will post -1.03 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $4.00 price target on shares of Ikena Oncology in a report on Monday, August 12th.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.